COVID-19 in a 16-Year-Old Adolescent With Mucopolysaccharidosis Type II: Case Report and Review of Literature |
Park, So Yun
(Department of Pediatrics, Keimyung University Dongsan Hospital, Keimyung University School of Medicine)
Kim, Heung Sik (Department of Pediatrics, Keimyung University Daegu Dongsan Hospital) Chu, Mi Ae (Department of Pediatrics, Keimyung University Daegu Dongsan Hospital) Chung, Myeong-Hee (Myung-hee Chung Pediatric Clinic) Kang, Seokjin (Department of Pediatrics, Keimyung University Dongsan Hospital, Keimyung University School of Medicine) |
1 | Furlan F, Rovelli A, Rigoldi M, Filocamo M, Tappino B, Friday D, et al. A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy. Ital J Pediatr 2018;44:128. DOI |
2 | Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577-83. DOI |
3 | Berger KI, Fagondes SC, Giugliani R, Hardy KA, Lee KS, McArdle C, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis 2013;36:201-10. DOI |
4 | Fdil N, Hammoud M, Sabir E, Lafha K, Laamani A, Alibou S, et al. The lysosomal storage diseases: a promising axis for COVID-19 future therapies. Am J Biomed Sci Res 2020;10:570-1. DOI |
5 | Purrello M, Di Pietro C, Rapisarda A, Mirabile E, Motta S, Sichel G, et al. Genetic characterization of general transcription factors TFIIF and TFIIB of Homo sapiens sapiens. Cytogenet Cell Genet 1995;69:75-80. DOI |
6 | Shapshak P. Molecule of the month, PDE4DIP. Bioinformation 2012;8:740-1. DOI |
7 | Tomatsu S, Gutierrez MA, Ishimaru T, Pena OM, Montano AM, Maeda H, et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005;28:743-57. DOI |
8 | Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011;6:72. DOI |
9 | Oyer HM, Sanders CM, Kim FJ. Small-molecule modulators of Sigma1 and Sigma2/TMEM97 in the context of cancer: foundational concepts and emerging themes. Front Pharmacol 2019;10:1141. DOI |
10 | Dejgaard SY, Presley JF. Rab18: new insights into the function of an essential protein. Cell Mol Life Sci 2019;76:1935-45. DOI |
11 | Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. Int J Infect Dis 2020;98:462-6. DOI |
12 | Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 2020;183:1043-1057.e15. DOI |
13 | Lindahl U, Couchman J, Kimata K, Esko JD. Proteoglycans and sulfated glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, et al., editors. Essentials of glycobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2015:207-21. |
14 | Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. DOI |
15 | Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The lysosome: a potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. FASEB J 2020;34:7253-64. DOI |
16 | Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011;50 Suppl 5:v4-12. DOI |
17 | Zimran A, Szer J, Revel-Vilk S. Impact of Gaucher disease on COVID-19. Intern Med J 2020;50:894-5. DOI |
18 | Ilan Y. β-Glycosphingolipids as mediators of both inflammation and immune tolerance: a manifestation of randomness in biological systems. Front Immunol 2019;10:1143. DOI |
19 | Pierzynowska K, Gaffke L, Wegrzyn G. Transcriptomic analyses suggest that mucopolysaccharidosis patients may be less susceptible to COVID-19. FEBS Lett 2020;594:3363-70. DOI |
![]() |